



HEALTH PARTNERS MEDICARE
PRIOR AUTHORIZATION REQUEST FORM

Health Partners Plans

Norditropin - Medicare

Phone: 215-991-4300

Fax back to: 866-371-3239

Health Partners Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL delay the review process.

Form with two columns: Patient Name and Prescriber Name. Fields include Member Number, Date of Birth, Line of Business, Address, City, State ZIP, Primary Phone, Fax, Office Contact, NPI, State Lic ID, Address, City, State ZIP, and Specialty/facility name.

REQUEST FOR EXPEDITED REVIEW: By checking this box and signing below, I certify that applying the 72 hour standard review timeframe may seriously jeopardize the life or health of the enrollee or the enrollee's ability to regain maximum function.

Drug Name:
Strength:
Directions / SIG:

Please attach any pertinent medical history including labs and information for this member that may support approval. Please answer the following questions and sign.

Q1. Is this request for a pediatric patient?
If No, go to 13.

Yes No

Q2. Has the patient been diagnosed by an endocrinologist with growth failure due to growth hormone deficiency via clinical assessment of appropriate auxological findings documented and attached (such as growth chart, height, height velocity, chronological and bone age), AND at least one of the following:

- A) Subnormal response to at least 2 provocative growth hormone (GH) stimulation tests (resulting in peak GH levels less than 10 ng/mL), OR
B) Subnormal response to at least one provocative GH stimulation test (resulting in peak GH level less than 10 ng/mL) AND subnormal insulin-like growth factor-1 (IGF-1) level, OR
C) Subnormal IGF-1 level AND panhypopituitarism (defined as deficiencies of at least 3 other pituitary hormones), pituitary disease, hypothalamic disease, hypothalamic/pituitary surgery, radiation therapy, or trauma?
Documentation must be attached.

Yes No

Q3. Has the patient been diagnosed by an endocrinologist with short stature associated with any of the following syndromes: Noonan syndrome, Turner syndrome, Prader-Willi syndrome (PWS)?
Must submit the following:

- A) Appropriate genetic test to confirm specific syndrome diagnosed, AND
B) Assessment of characteristic clinical manifestations consistent with the specific syndrome.
If Yes, go to 6.

Yes No

Q4. Has the patient been diagnosed by an endocrinologist with short stature due to being born small for gestational



HEALTH PARTNERS MEDICARE
PRIOR AUTHORIZATION REQUEST FORM

Health Partners Plans

Norditropin - Medicare

Phone: 215-991-4300

Fax back to: 866-371-3239

Health Partners Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL delay the review process.

Patient Name:

Prescriber Name:

age (SGA) with no catch-up growth by age 2 to 4 years?
Must submit documentation of diagnosis.
If Yes, go to 6.

Yes checkbox

No checkbox

Q5. Has the patient been diagnosed by an endocrinologist with idiopathic short stature (ISS)?
Must submit the following:

- A) Documentation of a height standard deviation score (SDS) less than -2.25 and associated with growth rates unlikely to allow one to reach normal adult height, AND
B) Documentation of growth chart, growth potential, impaired height velocity for age group, and bone age.

Yes checkbox

No checkbox

Q6. Is this a renewal request?
If No, go to 21.

Yes checkbox

No checkbox

Q7. Is there documentation of continued linear growth, linear potential remaining, and/or open epiphyses?
If No, go to 13.

Yes checkbox

No checkbox

Q8. Has the patient tolerated the medication without any significant side effects?

Yes checkbox

No checkbox

Q9. Is documentation attached including the growth chart, height velocity, chronological age, bone age (if available), growth rate, and insulin-like growth factor-1 (IGF-1) level?

Yes checkbox

No checkbox

Q10. Has the patient experienced an age appropriate annualized growth rate while on growth hormone therapy?

Yes checkbox

No checkbox

Q11. Given growth hormone therapy, is the patient's serum insulin-like growth factor-1 (IGF-1) concentration normal?
If Yes, go to 21.

Yes checkbox

No checkbox

Q12. Is there a plan to increase or decrease the dose of growth hormone until the serum insulin-like growth factor-1 (IGF-1) concentration is normal?
If Yes, go to 21.

Yes checkbox

No checkbox

Q13. Has the patient been diagnosed by an endocrinologist with adult growth hormone deficiency (GHD)?

Yes checkbox

No checkbox



HEALTH PARTNERS MEDICARE
PRIOR AUTHORIZATION REQUEST FORM

Health Partners Plans

Norditropin - Medicare

Phone: 215-991-4300

Fax back to: 866-371-3239

Health Partners Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL delay the review process.

Patient Name:

Prescriber Name:

Q14. Is the diagnosis of adult growth hormone deficiency (GHD) a result of childhood-onset GHD due to organic disease or as a result of panhypopituitarism, hypothalamic or pituitary surgery, hypothalamic or pituitary disease, radiation therapy, or trauma?

Must attach documentation.

If No, go to 16.

Yes checkbox

No checkbox

Q15. Has the diagnosis of adult growth hormone deficiency (GHD) been confirmed with a subnormal serum insulin-like growth factor-1 (IGF-1) while off growth hormone or prior to starting growth hormone therapy?

If yes, please attach documentation.

Yes checkbox

No checkbox

Q16. If the insulin-like growth factor-1 (IGF-1) value is questionable or uncertain, has adult growth hormone deficiency (GHD) been confirmed before replacement therapy is started, including subnormal provocative growth hormone stimulation tests while off growth hormone therapy for at least 1 month?

Must attach documentation.

Yes checkbox

No checkbox

Q17. Is this a renewal request?

If No, go to 21.

Yes checkbox

No checkbox

Q18. Has the patient tolerated the medication without any significant side effects?

Yes checkbox

No checkbox

Q19. Given continued growth hormone therapy, is the patients serum insulin-like growth factor-1 (IGF-1) concentration normal? Must attach documentation of IGF-1.

If Yes, go to 21.

Yes checkbox

No checkbox

Q20. Is there a plan to increase or decrease the dose of growth hormone until the serum insulin-like growth factor-1 (IGF-1) concentration is normal? Must attach plan.

Yes checkbox

No checkbox

Q21. Additional Information:

Q22. Duration:

12 months checkbox

Prescriber Signature

Date



**HEALTH PARTNERS MEDICARE
PRIOR AUTHORIZATION REQUEST FORM**

Health Partners Plans

Norditropin - Medicare

Phone: 215-991-4300

Fax back to: 866-371-3239

Health Partners Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL delay the review process.

Patient Name:

Prescriber Name:

2021 Medicare Prior Authorization Request